JP6073043B2 - 医薬品適用のための熱−動力学的混合 - Google Patents

医薬品適用のための熱−動力学的混合 Download PDF

Info

Publication number
JP6073043B2
JP6073043B2 JP2010522038A JP2010522038A JP6073043B2 JP 6073043 B2 JP6073043 B2 JP 6073043B2 JP 2010522038 A JP2010522038 A JP 2010522038A JP 2010522038 A JP2010522038 A JP 2010522038A JP 6073043 B2 JP6073043 B2 JP 6073043B2
Authority
JP
Japan
Prior art keywords
tkc
drug
thermodynamic
ktz
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010522038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536877A (ja
Inventor
クリス ブロウ
クリス ブロウ
ジェイムス ダブリュー． マギニティ
ジェイムス ダブリュー． マギニティ
デイブ エー． ミラー
デイブ エー． ミラー
ジェイムス シー． ディヌンツィオ
ジェイムス シー． ディヌンツィオ
ロバート オー．， サード ウィリアムス
ロバート オー．， サード ウィリアムス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2010536877A publication Critical patent/JP2010536877A/ja
Application granted granted Critical
Publication of JP6073043B2 publication Critical patent/JP6073043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010522038A 2007-08-21 2008-08-21 医薬品適用のための熱−動力学的混合 Active JP6073043B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95704407P 2007-08-21 2007-08-21
US60/957,044 2007-08-21
US5092208P 2008-05-06 2008-05-06
US61/050,922 2008-05-06
PCT/US2008/073913 WO2009026461A2 (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014148568A Division JP2014221816A (ja) 2007-08-21 2014-07-22 医薬品適用のための熱−動力学的混合
JP2016076558A Division JP2016121195A (ja) 2007-08-21 2016-04-06 医薬品適用のための熱−動力学的混合

Publications (2)

Publication Number Publication Date
JP2010536877A JP2010536877A (ja) 2010-12-02
JP6073043B2 true JP6073043B2 (ja) 2017-02-01

Family

ID=40378995

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010522038A Active JP6073043B2 (ja) 2007-08-21 2008-08-21 医薬品適用のための熱−動力学的混合
JP2014148568A Withdrawn JP2014221816A (ja) 2007-08-21 2014-07-22 医薬品適用のための熱−動力学的混合
JP2016076558A Withdrawn JP2016121195A (ja) 2007-08-21 2016-04-06 医薬品適用のための熱−動力学的混合
JP2018226362A Withdrawn JP2019052173A (ja) 2007-08-21 2018-12-03 医薬品適用のための熱−動力学的混合

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014148568A Withdrawn JP2014221816A (ja) 2007-08-21 2014-07-22 医薬品適用のための熱−動力学的混合
JP2016076558A Withdrawn JP2016121195A (ja) 2007-08-21 2016-04-06 医薬品適用のための熱−動力学的混合
JP2018226362A Withdrawn JP2019052173A (ja) 2007-08-21 2018-12-03 医薬品適用のための熱−動力学的混合

Country Status (6)

Country Link
US (6) US8486423B2 (OSRAM)
EP (1) EP2187968A4 (OSRAM)
JP (4) JP6073043B2 (OSRAM)
CN (1) CN101835492B (OSRAM)
CA (3) CA3076115C (OSRAM)
WO (1) WO2009026461A2 (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
JP2012501966A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
ES2776126T3 (es) * 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
CN102204868B (zh) * 2011-05-18 2014-01-22 北京化工大学 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺
US9821283B1 (en) * 2011-07-25 2017-11-21 Dispersol Technologies, Llc Direct probe sensed temperature method for speed change for heat sensitive portions of a thermokinetically melt blended batch
EP2895156B1 (en) 2012-09-17 2019-05-08 Pfizer Inc. Process for preparing therapeutic nanoparticles
ES3041833T3 (en) 2013-12-31 2025-11-14 Ascendia Pharmaceuticals Llc Pharmaceutical compositions for poorly water-soluble compounds
ES2834927T3 (es) 2014-03-14 2021-06-21 Pfizer Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
JP6535085B2 (ja) * 2014-04-18 2019-06-26 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー 熱動力学的に溶融ブレンドされるバッチの熱感受性部分を保護するための多段速度プロセス
US20170333404A1 (en) * 2014-11-03 2017-11-23 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
JP6730315B2 (ja) * 2015-01-20 2020-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体
EP3310354A4 (en) 2015-06-17 2018-12-12 Dispersol Technologies, LLC Improved formulations of deferasirox and methods of making the same
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
JP7112333B2 (ja) * 2016-05-09 2022-08-03 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー 改善された薬物製剤
CN109069652B (zh) 2016-05-13 2023-03-24 默克专利股份有限公司 用于熔体挤出应用的聚合物的粒度和分布
JP7376220B2 (ja) * 2017-09-11 2023-11-08 オースティンピーエックス リミテッド ライアビリティ カンパニー 熱動力学的に溶融ブレンドされるバッチの熱感受性部分用の、直接プローブにより感知した温度による、速度変更のための方法
AU2018335391A1 (en) * 2017-09-22 2020-03-26 AustinPx, LLC Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
PL3470133T3 (pl) 2017-10-13 2021-04-06 Dispersol Technologies, Llc Sposób temperaturowy z bezpośrednią detekcją sondą do zmiany prędkości wrażliwej temperaturowo części termokinetycznie topionej przez mieszanie partii
CN109663524B (zh) * 2017-10-13 2022-07-15 分散技术有限责任公司 用于热动力学熔体共混批次的热敏部分的速度改变的直接进样探头感测温度方法
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
MX2020006518A (es) * 2017-12-21 2020-10-28 Danisco Us Inc Gránulos de fusión en caliente, que contienen enzimas, que comprenden un desecante termotolerante.
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20220401579A1 (en) * 2019-11-30 2022-12-22 Dispersol Technologies, Llc Inclusion complexes of pharmaceuticals and cyclic oligomers
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물
EP4125923A1 (en) 2020-04-01 2023-02-08 Board of Regents, The University of Texas System Pharmaceutical compositions of niclosamide
WO2022120194A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
US20240108639A1 (en) * 2020-12-11 2024-04-04 Board Of Regents, The University Of Texas System Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
IL307454A (en) 2021-04-07 2023-12-01 Battelle Memorial Institute Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors
US20250000794A1 (en) * 2021-07-27 2025-01-02 Board Of Regents, The University Of Texas System Improved drug processing methods to increase drug loading
WO2023034844A1 (en) 2021-08-31 2023-03-09 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CN119453203A (zh) * 2025-01-09 2025-02-18 山东百农思达生物科技有限公司 一种含杀虫单和阿维菌素的复合微乳制剂及其制备工艺

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2319478A1 (fr) 1975-07-30 1977-02-25 Gen Electric Extrudeuse et procede d'extrusion de materiaux thermoplastiques
US4230615A (en) * 1978-11-21 1980-10-28 Carlew Chemicals Limited Process for controlled mixing in a high intensity mixer
US4628073A (en) 1984-10-03 1986-12-09 Monsanto Company Soft, rubbery, multiphase matrix material and methods for its production
US4789597A (en) 1987-01-12 1988-12-06 Fetherstonhaugh & Co. Incorporation of chemically reactive agents on resin particles
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH07159587A (ja) 1993-12-07 1995-06-23 Hitachi Ltd 樹脂性能モニタ
JPH07187998A (ja) * 1993-12-27 1995-07-25 Kao Corp 錠剤の製造方法
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5895790A (en) 1995-03-14 1999-04-20 Good; Elmer Thermosetting wide range polymer blends
DE19531067A1 (de) 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
DE69726729T2 (de) * 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6709146B1 (en) 2000-07-28 2004-03-23 David Little Thermokinetic mixer and method of using
CA2448825C (en) * 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
BRPI0407181A (pt) 2003-02-03 2006-02-07 Novartis Ag Formulação farmacêutica
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
KR101118930B1 (ko) * 2003-11-14 2012-03-14 아지노모토 가부시키가이샤 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제
WO2005053851A1 (en) 2003-11-26 2005-06-16 E.I. Dupont De Nemours And Company High pressure media milling system and process of milling particles
JP2005263758A (ja) * 2004-03-22 2005-09-29 Kirin Brewery Co Ltd 非晶質のｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キナゾリニル）オキシ］フェニル｝−ｎ’−プロピルウレア
KR101086254B1 (ko) 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
CA2603235A1 (en) 2005-03-28 2006-10-05 Bioresponse, Llc Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
JP2006347939A (ja) * 2005-06-15 2006-12-28 Tokyo Printing Ink Mfg Co Ltd 薬物高分子複合体の製造方法及び薬物高分子複合体
JP4429262B2 (ja) * 2005-12-09 2010-03-10 壽製薬株式会社 フェノフィブラートの固体分散体
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
JP2012047227A (ja) 2010-08-25 2012-03-08 Nippon Steel & Sumikin Metal Products Co Ltd ナット保持部材
US20140039031A1 (en) 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
US20170333404A1 (en) 2014-11-03 2017-11-23 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same

Also Published As

Publication number Publication date
US8486423B2 (en) 2013-07-16
US20200261473A1 (en) 2020-08-20
JP2010536877A (ja) 2010-12-02
CA3076115C (en) 2022-06-28
US10022385B2 (en) 2018-07-17
US20160250230A1 (en) 2016-09-01
US20130303630A1 (en) 2013-11-14
US20090053315A1 (en) 2009-02-26
JP2019052173A (ja) 2019-04-04
CN101835492A (zh) 2010-09-15
CA2990445A1 (en) 2009-02-26
US20230172949A1 (en) 2023-06-08
JP2014221816A (ja) 2014-11-27
CA3076115A1 (en) 2009-02-26
JP2016121195A (ja) 2016-07-07
CA2990445C (en) 2020-05-05
US10668085B2 (en) 2020-06-02
CN101835492B (zh) 2012-11-21
WO2009026461A2 (en) 2009-02-26
CA2697099C (en) 2018-02-20
US12023343B2 (en) 2024-07-02
EP2187968A2 (en) 2010-05-26
EP2187968A4 (en) 2013-02-20
US11439650B2 (en) 2022-09-13
CA2697099A1 (en) 2009-02-26
US20180360850A1 (en) 2018-12-20
WO2009026461A3 (en) 2009-04-30
US9339440B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
JP6073043B2 (ja) 医薬品適用のための熱−動力学的混合
CN103998037B (zh) 对高熔点疏水性化合物具有改进的生物利用度的药物组合物
US20160193151A1 (en) Dosage form incorporating an amorphous drug solid solution
ES2688278T3 (es) Forma de dosificación farmacéutica que comprende uno o más ingredientes activos antirretrovirales
WO2024095296A1 (en) Solvent free solid oral composition of bcs class iv drugs
RU2619840C1 (ru) Фармацевтическая композиция для лечения ВИЧ-инфекции
ES2932626T3 (es) Composición farmacéutica que comprende Aprepitant y método para su preparación
Jadhav et al. Solid dispersion: Solubility enhancement for poorly water soluble drug
US20240390285A1 (en) High-dose compressible dosage forms manufactured by simultaneous melt-coating and melt-granulation of active pharmaceutical ingredients
EP4008314A2 (en) Thermo-kinetic mixing for pharmaceutical applications
Williams III et al. Thermo-kinetic mixing for pharmaceutical applications
Chan The development of PVP-based solid dispersions using hot melt extrusion for the preparation of immediate release formulations
Keen Novel formulations and thermal processes for bioavailability enhancement of soluble and poorly soluble drugs
Alshetaili Solubility enhancement, mechanical properties and taste masking of poorly water soluble compounds by optimizing hot melt extrusion processing
CN119522100A (zh) 含有德拉马尼的固体分散体
Patel Dissolution Improvment of a Poorly Soluble Drug Using Hot Melt Extrusion Technique
PAUL MASTER OF PHARMACY
HK1196072A (en) Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound
HK1196072B (en) Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140820

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140912

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160114

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170104

R150 Certificate of patent or registration of utility model

Ref document number: 6073043

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250